RedHill Biopharma (RDHL) Income from Continuing Operations (2012 - 2023)
RedHill Biopharma (RDHL) posted quarterly Income from Continuing Operations of 58921000.0 for Q2 2023, up 791.8% year-over-year from 6607000.0 in Q2 2022, and up 844.05% quarter-over-quarter from 7919000.0 in Q1 2023.
RedHill Biopharma (RDHL) Income from Continuing Operations (2012 - 2023) Analysis & Trends
RedHill Biopharma (RDHL) has reported Income from Continuing Operations for 12 consecutive years, with 58921000.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Income from Continuing Operations rose 791.8% year-over-year to 58921000.0; the TTM figure through Jun 2023 stood at 40004000.0 (up 63.45% YoY), while the FY2025 annual figure was 429000.0, up 94.81% from the prior year.
- Income from Continuing Operations climbed to 58921000.0 in Q2 2023 per RDHL's latest filing, from 7919000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 58921000.0 in Q2 2023 and bottomed at 142200000.0 in Q4 2021.
- Historically, Income from Continuing Operations has averaged 1356111.11 across 5 years, with a median of 10409000.0 in 2020.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations tumbled 1449.66% — and 2023, when it jumped 791.8%.
- RedHill Biopharma's Income from Continuing Operations stood at 11837000.0 in 2019, then retreated by 10.99% to 10536000.0 in 2020, then sank by 1449.66% to 142200000.0 in 2021, then soared by 51.11% to 69521000.0 in 2022, then soared by 184.75% to 58921000.0 in 2023.
- Business Quant data shows RDHL's Income from Continuing Operations at 58921000.0 in Q2 2023, 7919000.0 in Q1 2023, and 69521000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 58.92 Mn |
| Mar 31, 2023 | -7.92 Mn |
| Dec 31, 2022 | -69.52 Mn |
| Sep 30, 2022 | -21.49 Mn |
| Jun 30, 2022 | 6.61 Mn |
| Mar 31, 2022 | 12.73 Mn |
| Dec 31, 2021 | -142.20 Mn |
| Sep 30, 2021 | 13.41 Mn |
| Jun 30, 2021 | 20.65 Mn |
| Mar 31, 2021 | 13.44 Mn |
| Dec 31, 2020 | 10.54 Mn |
| Sep 30, 2020 | 10.28 Mn |
| Jun 30, 2020 | 8.95 Mn |
| Mar 31, 2020 | 16.45 Mn |
| Dec 31, 2019 | 11.84 Mn |
| Sep 30, 2019 | 10.22 Mn |
| Jun 30, 2019 | 14.13 Mn |
| Mar 31, 2019 | 8.56 Mn |
| Dec 31, 2018 | 12.40 Mn |
| Sep 30, 2018 | 9.39 Mn |